LOGIN  |  REGISTER
Cue Biopharma
C4 Therapeutics

LifeMD to Participate in Two Investor Conferences in September

August 30, 2023 | Last Trade: US$14.05 0.25 -1.75

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD) today announced that management will be participating in two upcoming investor conferences in September.

  • H.C. Wainwright 25th Annual Global Investment Conference, September 11-13, 2023 at the Lotte New York Palace Hotel in New York City. Management will deliver a company presentation on Wednesday, September 13th at 3:30 p.m. Eastern Time and will be available for one-on-one meetings with investors. A live and archived webcast of the presentation will be available in the Investors section of LifeMD’s website.
  • Cantor Fitzgerald Global Healthcare Conference, September 26-28, 2023 at the InterContinental New York Barclay in New York City. Management will participate in a fireside chat on Thursday, September 28th at 9:45 a.m. Eastern Time and will be available for one-on-one meetings during the event.

About LifeMD

LifeMD is a direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics and specialized treatment for men’s and women’s health, allergy & asthma and dermatologic conditions. By leveraging its proprietary technology platform, 50-state affiliated medical group and nationwide mail-order pharmacy network, LifeMD is making top-notch healthcare available and affordable to anyone. To learn more, go to LifeMD.com.

Company Contact:
LifeMD, Inc.
Marc Benathen, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page